Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number?
作者信息
Sauer Andrew J
机构信息
Department of Cardiovascular Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA.
出版信息
J Am Coll Cardiol. 2022 Jul 5;80(1):19-21. doi: 10.1016/j.jacc.2022.04.037.
PMID:35772912
Abstract
摘要
相似文献
1
Empagliflozin and Elderly Patients With Preserved Ejection Fraction Heart Failure: Is Age Just a Number?恩格列净与射血分数保留的老年心力衰竭患者：年龄只是一个数字吗？
J Am Coll Cardiol. 2022 Jul 5;80(1):19-21. doi: 10.1016/j.jacc.2022.04.037.
2
Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction.简要研究：恩格列净用于射血分数保留的心力衰竭患者。
Clin Med (Lond). 2022 Jan;22(1):75-76. doi: 10.7861/clinmed.rib.22.1.1.
3
Evidence for empagliflozin in heart failure with preserved ejection fraction (HFpEF).恩格列净在射血分数保留型心力衰竭（HFpEF）中的证据。
Drug Ther Bull. 2023 Feb;61(2):22-23. doi: 10.1136/dtb.2022.000060. Epub 2022 Dec 12.
4
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).恩格列净对射血分数降低的心力衰竭合并 2 型糖尿病或糖尿病前期患者左心室容积的影响（SUGAR-DM-HF）。
Circulation. 2021 Feb 9;143(6):516-525. doi: 10.1161/CIRCULATIONAHA.120.052186. Epub 2020 Nov 13.
5
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净用于射血分数保留的心力衰竭
N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470.
6
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净用于射血分数保留的心力衰竭
N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470.
7
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净用于射血分数保留的心力衰竭
N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470.
8
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.恩格列净用于射血分数保留的心力衰竭
N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470.
9
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Reply.恩格列净用于射血分数保留的心力衰竭。回复
N Engl J Med. 2022 May 26;386(21):e57. doi: 10.1056/NEJMc2118470.
10
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.恩格列净改善射血分数保留的心力衰竭患者的结局，与年龄无关。
J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040.
引用本文的文献
1
Management of Heart Failure With Preserved Ejection Fraction in Elderly Patients: Effectiveness and Safety.老年射血分数保留的心力衰竭的管理：有效性和安全性
Cureus. 2023 Feb 15;15(2):e35030. doi: 10.7759/cureus.35030. eCollection 2023 Feb.
2
Using real-world data for supporting regulatory decision making: Comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data.利用真实世界数据支持监管决策：恩格列净随机临床试验与真实世界数据的心血管及安全性结局比较
Front Pharmacol. 2022 Aug 30;13:928121. doi: 10.3389/fphar.2022.928121. eCollection 2022.
Zotero 插件